TickerTalks
Browse all tickers →
TickerTalks›$MGNX
MGMGNX

MacroGenics, Inc.

$MGNX·$207M·Biotechnology·Healthcare
$3.25-3.6%YTD+112.4%1Y+92.3%
Price updated 8h ago·X counts updated 5d ago
MGMGNX
$MGNXMacroGenics, Inc.
$3.25-3.56%32 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $MGNX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

32X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $MGNX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 76% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-18

Chatter is bullish on MacroGenics. Gilead exercised its option to license a second MGNX preclinical bispecific program triggering a $10M milestone payment — MGNX remains eligible for up to ~$1.6B in additional development/regulatory/commercial milestones. Bulls frame MGNX at ~$258M market cap versus ~$327M in pro-forma cash, two ADC readouts in the back half (with B7H3 acknowledged as crowded), and one undisclosed ADC entering the clinic in 3Q. Non-Topo1 payload ADC diversification is called out as strategically crucial.

Read what X is saying about $MGNX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $MGNX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

MacroGenics triggered Gilead's second option exercise — $10M milestone plus $1.6B potential, with BofA buying 564K shares.

MacroGenics is a specialty-oncology biopharma whose 2026 story is substantive — Gilead exercising its option to license a second MGNX preclinical bispecific program triggers a $10M milestone payment, with up to ~$1.6B in additional development/regulatory/commercial milestones.

  • The P&L is clinical-stage: Q2 revenue grew 57.5% YoY to $21M at a -161% operating margin and EPS of -$0.58, with trailing EPS beats of 498% and miss of 1.8% — the +498% beat two prints ago reflects specific milestone-driven revenue recognition.
  • The specific capital-markets positioning is substantive: MGNX at ~$258M market cap vs ~$327M in pro-forma cash (negative enterprise value), two ADC readouts in the back half (with B7H3 acknowledged as crowded), and Bank of America buying 564,094 shares — the setup is explicitly described as 'Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead.'

At 60% of its 52-week range and 10% above the 200-day with volume at 1.9x average going into Nov 11 earnings, the setup is late-cycle hot-momentum but on fundamentals. A positive ADC readout plus continued milestone-driven revenue is the trigger for continuation; a safety-signal or any Gilead-partnership-related delay is the invalidation.

Agrees with X sentimentThe $258M market cap vs $327M pro-forma cash framing is a specific valuation anchor, and the Gilead second-option exercise with $10M milestone is grounded. The B7H3 crowded acknowledgment is honest sector-caveat.

What to watch: Nov 11 Q3 earnings and any ADC readout — pipeline-advancement outcome, cash runway, Gilead-partnership commentary, and FY27 guide. Positive ADC data plus milestone revenue is the trigger; safety signal is the invalidation.

On the calendar: 2026-11-11 — Q3 earnings

event ahead 30dmilestone catalysts

Read the AI verdict on $MGNX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops bispecific and Fc-optimized antibody cancer therapies; lead program vobramitamab duocarmazine targets solid tumors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $MGNX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $MGNX

Neutral — Develops bispecific and Fc-optimized antibody cancer therapies; lead program vobramitamab duocarmazine targets solid tumors.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-49.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-40.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-148%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$0.31$-0.08+498.2%
Q1 2026May 13, 2026$-0.58$-0.57-1.8%
Q4 2025Mar 9, 2026$-0.22$-0.42+47.6%
Q3 2025Nov 12, 2025$0.27$-0.48+156.3%
Next earningsWed, Nov 11·consensus EPS $-0.10

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$20.8M+57.5%46.0%-161%$-0.58$-36.2M
Q4 FY25$41.2M+132.5%71.3%-29.3%$-0.22$42.8M
Q3 FY25$72.8M-34.2%81.6%25.6%$0.27$-30.6M
Q2 FY25$22.2M+106.0%51.4%-165%$-0.57$-47.7M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$109.8M$103.8M – $115.9M-$1.76-$2.62 – -$0.914
FY27$90.6M$70.1M – $111.1M-$1.64-$2.23 – -$1.054
FY28$88.2M$58.7M – $124.4M-$2.05-$3.35 – -$1.434
FY29$90.0M$56.5M – $123.8M-$2.04-$3.04 – -$1.052
FY30$128.0M$80.3M – $176.2M-$1.01-$1.51 – -$0.522

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.52%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-17.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-3.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 56.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.215-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 19Peters Jeffrey StuartSenior VP, GC, and Secretary31.1K sh$129K
+ 20 other (11 exempts · 9 awards) in window

See when $MGNX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 88-K — Item 5.02: Officer or director change
AI summary

MacroGenics announced that director Karen Ferrante, M.D., has resigned from the Board of Directors effective September 1, 2026, citing personal reasons. Her departure was not due to any disagreement with management or the board on matters of company operations, policies, or practices. The company will evaluate whether to replace her seat, though no immediate plans for a new director appointment were disclosed in this filing.

8-KAcquisition completedJul 78-K — Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary

MacroGenics, Inc. completed the sale of its GMP manufacturing and CDMO business to Bora Pharmaceuticals Co., Ltd. (Taiwan) and Bora Biologics USA, LLC on June 30, 2026, pursuant to an Asset Purchase Agreement signed May 11, 2026. The purchase price was $122.5 million before transaction fees and subject to customary post-closing adjustments. Bora assumed responsibility for the CDMO operations at the Rockville, Maryland facility and the Frederick, Maryland warehouse. This is a strategic asset divestiture that enables MacroGenics to focus on its drug pipeline while generating $122.5 million in proceeds.

8-KShareholder voteMay 208-K — Item 5.07: Shareholder vote
AI summary

MacroGenics, Inc. (MGNX) filed an 8-K on May 19, 2026 disclosing annual shareholder meeting vote results (Item 5.07). MacroGenics is a Rockville, Maryland-based clinical-stage biopharmaceutical company listed on Nasdaq. Annual meeting results are routine governance disclosures.

8-KMaterial agreementMay 128-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

MacroGenics Inc. (MGNX) filed an 8-K covering two items: a material definitive agreement (Item 1.01) and a Regulation FD disclosure (Item 7.01). The company entered into a new collaboration or licensing arrangement and simultaneously disclosed related information to ensure fair public access. The agreement may involve milestone payments, royalties, or co-development rights with a strategic partner. Full agreement details and any investor presentation materials are filed as exhibits.

8-KMaterial agreementMay 48-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

MacroGenics Inc. (MGNX) filed an 8-K disclosing a new material definitive agreement (Item 1.01) alongside other material events (Item 8.01). The clinical-stage biopharmaceutical company entered into a collaboration, licensing, or supply agreement with strategic or financial terms material to the business. The Item 8.01 may cover related announcements or developments tied to the agreement. Full agreement terms are included as exhibits to the filing.

+ 16 other (8 13Gs · 3 earnings 8-Ks · 2 10-Qs · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumorsglobenewswire.com·2d agoIs MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?zacks.com·8d agoStock Picks From Seeking Alpha's September 2026 New Analystsseekingalpha.com·10d agoMacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conferenceglobenewswire.com·38d agoMacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Aheadseekingalpha.com·38d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $MGNX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport